Pharmaceutical Biotechnology

The working group Pharmaceutical Biotechnology is focused on the development of novel recombinant binding molecules and cellular models for biomedical research and the development of pharmaceutical compounds.

Fig. 1: SARS-CoV-2 RBD in complex with specific Nanobodies — SARS-CoV-2 spike receptor binding domain (RBD, grey) in complex with two specific Nanobodies (blue & red). For further information see Wagner et al. 2021, doi: 10.15252

Selection of current research topics (University of Tuebingen):

Predictive diagnosis of immune-associated diseases. Nanobodies for in vivo imaging of cellular immune targets (in collaboration with Prof. Bernd Pichler, WSIC)
Nano- and Chromobodies for structural and functional analysis of the mitochondrial outer membrane (MOM) associated components Miro1, Milton/TRAK and Drp1 (in collaboration with the members of MOMbrane)
Generation of Nanobody-modified Biosensors for Targeted Visualization of Potassium Channels (in collaboration with Prof. Robert Lukowski, Pharmacology, University of Tuebingen)
Development and application of SARS-CoV-2 specific nanobodies